B. Dymock

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

A. Poulsen, A. William, B. Dymock, 2011, Leukemia.

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

J. Wood, A. William, B. Dymock, 2012, Leukemia.